Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph Peuskens

Showing results (41-50 of 75) with videos related to

Pageof 8
Sort By:
Schizophrenia Research|October 13, 2009
Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST)Han Boter, Joseph Peuskens, Jan Libiger, et al.
Psychotherapy and Psychosomatics|October 26, 2005
Comparison of changes in physical self-concept, global self-esteem, depression and anxiety following two different psychomotor therapy programs in nonpsychotic psychiatric inpatientsJan Knapen, Peter Van de Vliet, Herman Van Coppenolle, et al.
Psychiatry Research|August 4, 2009
Abnormal transbilayer distribution of phospholipids in red blood cell membranes in schizophreniaPhilippe Nuss, Cedric Tessier, Florian Ferreri, et al.
American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics|February 10, 2011
Age at onset of psychotic disorder: cannabis, BDNF Val66Met, and sex-specific models of gene-environment interactionJeroen Decoster, Jim van Os, Gunter Kenis, et al.
The Journal of Clinical Psychiatry|November 17, 2006
Screening for diabetes and other metabolic abnormalities in patients with schizophrenia and schizoaffective disorder: evaluation of incidence and screening methodsRuud van Winkel, Marc De Hert, Dominique Van Eyck, et al.
The Journal of Clinical Psychiatry|March 20, 2008
Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorderRuud van Winkel, Marc De Hert, Martien Wampers, et al.
Bipolar Disorders|February 15, 2008
Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorderRuud van Winkel, Marc De Hert, Dominique Van Eyck, et al.
Schizophrenia Bulletin|August 31, 2006
A case series: evaluation of the metabolic safety of aripiprazoleMarc De Hert, Linda Hanssens, Ruud van Winkel, et al.
Therapeutic Advances in Psychopharmacology|August 25, 2015
Treatment response, safety, and tolerability of paliperidone extended release treatment in patients recently diagnosed with schizophreniaLars Helldin, Joseph Peuskens, Roland Vauth, et al.
Psychiatry Research|April 22, 2010
Considering a frame of reference for physical activity research related to the cardiometabolic risk profile in schizophreniaDavy Vancampfort, Jan Knapen, Michel Probst, et al.
Pageof 8

Showing results (41-50 of 75) with videos related to

Sort By:
Pageof 8
Schizophrenia Research|October 13, 2009
Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST)Han Boter, Joseph Peuskens, Jan Libiger, et al.
Psychotherapy and Psychosomatics|October 26, 2005
Comparison of changes in physical self-concept, global self-esteem, depression and anxiety following two different psychomotor therapy programs in nonpsychotic psychiatric inpatientsJan Knapen, Peter Van de Vliet, Herman Van Coppenolle, et al.
Psychiatry Research|August 4, 2009
Abnormal transbilayer distribution of phospholipids in red blood cell membranes in schizophreniaPhilippe Nuss, Cedric Tessier, Florian Ferreri, et al.
American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics|February 10, 2011
Age at onset of psychotic disorder: cannabis, BDNF Val66Met, and sex-specific models of gene-environment interactionJeroen Decoster, Jim van Os, Gunter Kenis, et al.
The Journal of Clinical Psychiatry|November 17, 2006
Screening for diabetes and other metabolic abnormalities in patients with schizophrenia and schizoaffective disorder: evaluation of incidence and screening methodsRuud van Winkel, Marc De Hert, Dominique Van Eyck, et al.
The Journal of Clinical Psychiatry|March 20, 2008
Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorderRuud van Winkel, Marc De Hert, Martien Wampers, et al.
Bipolar Disorders|February 15, 2008
Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorderRuud van Winkel, Marc De Hert, Dominique Van Eyck, et al.
Schizophrenia Bulletin|August 31, 2006
A case series: evaluation of the metabolic safety of aripiprazoleMarc De Hert, Linda Hanssens, Ruud van Winkel, et al.
Therapeutic Advances in Psychopharmacology|August 25, 2015
Treatment response, safety, and tolerability of paliperidone extended release treatment in patients recently diagnosed with schizophreniaLars Helldin, Joseph Peuskens, Roland Vauth, et al.
Psychiatry Research|April 22, 2010
Considering a frame of reference for physical activity research related to the cardiometabolic risk profile in schizophreniaDavy Vancampfort, Jan Knapen, Michel Probst, et al.
Pageof 8